Ibuprofen Gen.Orph

Ibuprofen Gen.Orph is a medicine used to treat ‘patent ductus arteriosus’ in newborn premature babies who were born six or more weeks too early (less than 34 weeks gestational age). Patent ductus arteriosus is a condition where the ductus arteriosus (the blood vessel that allows blood to bypass the baby’s lungs before birth) fails to close after birth. This causes heart and lung problems in the baby. Ibuprofen Gen.Orph is a ‘generic medicine’. This means that Ibuprofen Gen.Orph contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Ibuprofen Gen.Orph is Pedea. For more information on generic medicines, see the question\-and\-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf). Ibuprofen Gen.Orph contains the active substance ibuprofen.